DECN — Decision Diagnostics Share Price
Last trade - 00:00- $0.00m
- $3.14m
- $1.98m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -235.24% | ||
| Return on Equity | -957.3% | ||
| Operating Margin | -84.42% | ||
Financial Summary
| Year End 31st Dec | Unit | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 1.09 | 1.88 | 2.24 | 2.38 | 1.98 | n/a | n/a | 30.9% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Decision Diagnostics Corp. is specialized in prescription, non-prescription diagnostics and home testing products. The Company is a provider of prescription drugs, home testing products for the chronically ill, a fulfillment provider of direct to patient diabetes programs, and a developer of cell phone centric, e-health products and technology. Through its subsidiary, PharmaTech Solutions, Inc., the Company provides blood glucose home testing devices like GenUltimate! and PetSure! test strips and GenUltimate!4Pets monitoring system. It also provides smart phone based electronic medical record (EMR) applications to be used by physicians at the point of care. These mobile applications allow physicians to access and update their patients’ histories, medication data and care guidelines. The Company develops products that offer solutions to medical care professionals and management by providing physicians with essential information at their fingertips.
Directors
- Last Annual
- December 31st, 2020
- Last Interim
- September 30th, 2021
- Incorporated
- March 2nd, 2001
- Public Since
- February 8th, 2002
- No. of Employees
- 5
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 357,870,583
- Address
- SUITE 300, 2660 TOWNSGATE ROAD, WESTLAKE VILLAGE, 91361
- Web
- https://www.decisiondiagnostics.co/
- Phone
- +1 8054461973
- Auditors
- L.L. Bradford & Company, LLC
Upcoming Events for DECN
Similar to DECN
Aamaxan Transport
Pink Sheets on Nasdaq
ACCUSTEM SCIENCES
Pink Sheets on Nasdaq
Acutus Medical
Pink Sheets on Nasdaq
ADM Tronics Unlimited
Pink Sheets on Nasdaq
Advanced Biomedical Technologies
Pink Sheets on Nasdaq
FAQ
As of Today at 20:14 UTC, shares in Decision Diagnostics are trading at $0.00. This share price information is delayed by 15 minutes.
Shares in Decision Diagnostics last closed at $0.00 and the price had moved by -99% over the past 365 days. In terms of relative price strength the Decision Diagnostics share price has underperformed the S&P500 Index by -99.16% over the past year.
There is no consensus recommendation for this security.
Decision Diagnostics does not currently pay a dividend.
Decision Diagnostics does not currently pay a dividend.
Decision Diagnostics does not currently pay a dividend.
To buy shares in Decision Diagnostics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.00, shares in Decision Diagnostics had a market capitalisation of $0.00m.
Here are the trading details for Decision Diagnostics:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: DECN
Based on an overall assessment of its quality, value and momentum Decision Diagnostics is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Decision Diagnostics. Over the past six months, its share price has underperformed the S&P500 Index by -9.44%.
As of the last closing price of $0.00, shares in Decision Diagnostics were trading -98.89% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Decision Diagnostics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Decision Diagnostics' management team is headed by:
- Robert Jagunich - DRC
- William Lyons - DRC